GeoVax Labs, Inc. has entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin® in combination with immune checkpoint inhibitors. The licensed technology supports the use of gene-directed enzyme prodrug therapy to enhance the anti-tumor activity of checkpoint blockade, which has transformed cancer care but still leaves many patients without durable responses.
The agreement provides GeoVax with global rights to patent applications and associated know-how covering the combination of Gedeptin with immune checkpoint inhibitors within a defined field of use. This intellectual property estate is intended to support GeoVax's current and planned clinical programs evaluating Gedeptin in combination with ICIs, including its recently announced neoadjuvant strategy in head and neck cancer and ongoing evaluation of additional solid tumor indications.
David A. Dodd, Chairman and Chief Executive Officer of GeoVax, stated that as checkpoint inhibitors continue to move earlier in treatment paradigms, including first-line and neoadjuvant settings, Gedeptin's localized tumor-debulking and immune-sensitizing mechanism may provide an important opportunity to enhance and extend immune checkpoint inhibitor efficacy. The licensed Emory technology reinforces the scientific rationale for combining Gedeptin with ICIs to potentially convert immunologically 'cold' tumors into more responsive targets.
GeoVax has previously reported encouraging clinical and translational data demonstrating that Gedeptin's intratumoral delivery approach can induce localized tumor cell death while promoting immune activation within the tumor microenvironment. This effect may be complementary to systemic checkpoint inhibition. The company has announced plans to evaluate Gedeptin in combination with immune checkpoint inhibitors in a Phase 2 neoadjuvant clinical trial in head and neck squamous cell carcinoma, as well as preclinical assessments in additional solid tumor settings.
The Emory license provides a strengthened intellectual property foundation to support these efforts and potential future partnerships. GeoVax continues to evaluate strategic collaboration opportunities related to both the clinical development and potential commercialization of Gedeptin-based combination therapies. Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers and has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer.
For more information about GeoVax's broader pipeline and development priorities, visit https://www.geovax.com. The company's priority program is GEO-MVA, a Modified Vaccinia Ankara-based vaccine targeting Mpox and smallpox, which is advancing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026.
